A recent study by Wall and colleagues in 2019 supported this hypothesis by measuring the metastatic burden in lung and liver as well as MMP-2 levels in dependency of the treatment with lidocaine and the Src-inhibitor bosutinib in a 4T1 mouse tumor model [106]. Here, SRC is linked to neoplasm.